# Gland Pharma shares hit 52-week high on 58% profit jump 2026-11-09T06:31:52+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 3 independent outlets Gland Pharma shares hit a 52-week high of Rs 3,352 on Monday, 9 November, rising nearly 7% despite a broader market sell-off, after the company reported a 58% jump in net profit for the September 2026 quarter. The stock touched Rs 3,345 on the NSE, according to The Economic Times, while Livemint reports the intraday high at Rs 3,352. Revenue rose 23% year-on-year to Rs 1,834 crore. Livemint puts net profit at Rs 291 crore, while The Economic Times reports Rs 290.8 crore. The CDMO business contributed 45% of revenue and grew 31% year-on-year, The Economic Times reports. Livemint notes the stock has gained 93.87% year-to-date. Business Standard reports Gland Pharma was among several pharma stocks that rallied on Monday, with the Nifty Pharma index hitting a record high of 29,224.85. No brokerage target was updated in the new sources. The stock's five-year return remains negative at an 8.26% decline, Livemint notes. ## Indian Opinion Analysis Livemint, The Economic Times and Business Standard all report Gland Pharma's Q2 results from the same company release, giving near-identical revenue, profit and margin figures. Livemint leads with the 52-week high and the 93% YTD gain, while The Economic Times emphasises segment-level detail, such as CDMO's 45% revenue share and the 11 ANDA filings. Business Standard places Gland's move within a broader pharma-sector rally, noting the Nifty Pharma index record. Livemint's framing of 'defying the market sell-off' adds a contrarian angle missing from the other two. The uniform financial numbers confirm consensus, but the different lead facts show each outlet chose a distinct narrative hook. The next tangible item is whether the stock sustains its rally after the 93% YTD gain, as Livemint's headline already questions. ## Coverage Coverage: 3 sources, 3 neutral - livemint.com (neutral report) Leads with stock price action and YTD return, adds question about rally continuing - economictimes.indiatimes.com (neutral report) Leads with Q2 results, adds management comment and segment details - business-standard.com (neutral report) Places Gland Pharma in broader pharma sector rally, emphasises CDMO theme This brief was synthesised by AI from the 3 sources linked above, so one read covers every framing they carry. Update, 9 November 2026: this story now draws on 3 sources. Last updated 2026-11-09T07:27:19+00:00. Tags: Gland Pharma, Motilal Oswal, Srinivas Sadu Canonical: https://indianopinion.org/gland-pharma-hits-52-week-high-after-q2-profit-jumps-58/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/gland-pharma-hits-52-week-high-after-q2-profit-jumps-58/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/